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Abstract
IMPORTANCE Higher plasma concentrations of vitamin B12 have been associated with mortality in
elderly and hospitalized populations, including patients with chronic kidney disease, but the
association of plasma concentrations of vitamin B12 with mortality in the general population
remains unclear.
OBJECTIVE To investigate the association of plasma concentrations of vitamin B12 with all-cause
mortality.
DESIGN, SETTING, AND PARTICIPANTS This longitudinal cohort study used post hoc analysis to
examine data from participants of the Prevention of Renal and Vascular End-stage Disease Study in
Groningen, the Netherlands. Participants included individuals who completed the second screening
visit beginning January 1, 2001, excluding those who were missing values of vitamin B12 plasma
concentrations or used vitamin B12 supplementation. Follow-up time was defined between the
beginning of the second screening round to end of follow-up on January 1, 2011. Data analysis was
conducted from October 2, 2018, to February 22, 2019.
EXPOSURES Plasma vitamin B12 concentration level.
MAIN OUTCOMES AND MEASURES Death as recorded by the Central Bureau of Statistics of
Groningen, the Netherlands.
RESULTS A total of 5571 participants (mean [SD] age, 53.5 [12.0] years; 2830 [50.8%] men) were
included in analyses. Median (interquartile range) plasma concentration of vitamin B12 was 394.42
(310.38-497.42) pg/mL. During the median (interquartile range) of 8.2 (7.7-8.9) years of follow-up,
226 participants (4.1%) died. According to quartiles of the distribution of plasma vitamin B12
concentration levels, mortality rates were 33.8 deaths per 10 000 person-years for the quartile with
the lowest plasma concentration of vitamin B12 and 65.7 deaths per 10 000 person-years for the
quartile with the highest plasma concentration of vitamin B12. After adjustment for multiple clinical
and laboratory variables, Cox regression analyses found a significant association between higher
vitamin B12 plasma concentration level and increased risk of all-cause mortality (hazard ratio per 1-SD
increase, 1.25 [95% CI, 1.06-1.47]; P = .006).
CONCLUSIONS AND RELEVANCE These findings suggest that higher levels of plasma
concentrations of vitamin B12 were associated with increased risk of all-cause mortality after
adjusting for age, sex, renal function, and other clinical and laboratory variables. The mechanisms
underlying this association remain to be established.
JAMA Network Open. 2020;3(1):e1919274. doi:10.1001/jamanetworkopen.2019.19274
Key Points
Question Are plasma concentrations of
vitamin B12 associated with risk of
all-cause mortality among adults from
the general population of the
Netherlands?
Findings In this population-based
cohort study including 5571 adults,
higher plasma concentrations of vitamin
B12 were associated with a 25%
increased adjusted risk of all-cause
mortality per 1-SD increase.
Meaning These findings suggest that
higher plasma concentrations of vitamin
B12 are associated with all-cause
mortality, independent of traditional
risk factors.
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Introduction
Vitamin B12 is a hydrosoluble vitamin that plays a substantial role in 1-carbon metabolism. The
1-carbon pathway is involved in several biological functions beyond fetal development, such as
mitochondrial metabolism, immune response, and nucleotide homeostasis in
nonproliferative tissues.1
While the deleterious effects of vitamin B12 deficiency, such as anemia, neuropsychiatric
symptoms, and other clinical manifestations, are well established,2 the potential association of high
plasma concentrations of vitamin B12 with adverse health outcomes has not been fully explored.
3
Indeed, a potential association of high vitamin B12 plasma concentrations with excess mortality has
been assessed in elderly3-9 and hospitalized10,11 populations, but it has not been explored in the
general population, to our knowledge.
An association of high plasma concentrations of vitamin B12 with increased risk of all-cause
mortality has been reported among patients undergoing dialysis treatment.12 It has also been found
that impaired renal function is associated with high plasma concentrations of vitamin B12.
13,14
Furthermore, it has been found that combined supplementation of folic acid, vitamin B6, and vitamin
B12 results in more rapid decline of renal function and an increase in occurrence of vascular events in
patients with diabetic nephropathy.15 Taken together, these findings underscore the importance of
further exploration of a possible role of chronic kidney disease (CKD) in the association of plasma
concentrations of vitamin B12 with all-cause mortality.
Therefore, this study aimed to assess the association of plasma concentrations of vitamin B12
with all-cause mortality in a population-based cohort study. In addition, we aimed to investigate
whether findings were further associated with CKD or age, considering that approximately 35% of
the elderly population has some degree of CKD.16 The Prevention of Renal and Vascular End-stage
Disease (PREVEND) study is particularly suitable for such aims, since it has a wide age range and its
design is enriched with a CKD component.
Methods
Study Cohort
The PREVEND Study is a prospective population-based cohort study in the city of Groningen, the
Netherlands. The design of the PREVEND Study has been described in detail elsewhere.17 Briefly,
from 1997 to 1998, all residents from Groningen aged 28 to 75 years were invited to participate. A
total of 40 856 individuals (47.8%) responded to the invitation to participate. From this group,
30 890 individuals had a urinary albumin concentration of less than 10 mg/L and 9966 individuals
had a urinary albumin concentration of 10 mg/L or higher in their morning urine sample. After
exclusion of individuals with type 1 diabetes and women who were pregnant, 7768 individuals with a
urinary albumin concentration of 10 mg/L or higher and a randomly selected control group of 3395
individuals with a urinary albumin concentration of less than 10 mg/L were invited for further
investigations in an outpatient clinic. A total of 8592 individuals completed an extensive
examination. The PREVEND Study cohort was designed to include any people who met the inclusion
criteria, regardless of race/ethnicity, which was recorded according to self-report and included in the
analysis owing to potential racial/ethnic disparities in all-cause mortality.18
We used data from 6894 participants who completed the second screening, starting January 1,
2001, excluding 1265 individuals with missing samples for assessment of vitamin B12 plasma
concentrations and 58 individuals for use of injectable vitamin B12 supplementation, leaving a cohort
of 5571 participants with complete information for the analysis (Figure 1). In this group, less than 1%
of data on laboratory variables was missing. Participants lost to follow-up were considered as
censored data. Educational level was categorized into low (ie, no, primary, basic vocational, and
secondary education), medium (ie, senior secondary vocational and general senior secondary
education), and high (higher professional and higher academic education) according to the
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International Standard Classification of Education.19 Drug dispensing data of injectable vitamin B12
supplementation was retrieved from the University Groningen Pharmacy dispensing database
IADB.nl.20 This report follows the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) reporting guideline. The protocol for the PREVEND study was approved by
the local ethics committee of the University Medical Center Groningen. All participants provided written
informed consent, and all procedures were conducted according to the Declaration of Helsinki.21
Laboratory Measurements
Laboratory measurements were performed at the Central Laboratory of the University Medical
Center Groningen, the Netherlands. Hematologic measurements, including hemoglobin, hematocrit,
and mean corpuscular volume, were measured on a Coulter Counter STKS sample testing system
(Coulter Corp) in fresh venous blood according to standard procedures. Plasma glucose level was
measured directly after blood sampling. Ethylene diamine tetraacetic acid–anticoagulated plasma
samples and sera were stored at −80 °C until analysis.
Vitamin B12 plasma concentrations were measured on a Roche platform, using the validated
Elecsys Vitamin B12 II assay (Roche Diagnostics). The performance of Elecsys Vitamin B12 II has been
reported in greater detail elsewhere.22
Total cholesterol (TC), triglyceride, serum creatinine, and serum cystatin C levels were measured
using standard protocols, as described previously.23-25 Serum ferritin levels were measured using
immunoassay, and serum transferrin levels were measured using immunoturbidimetric assay (Roche
Diagnostics). Homocysteine concentrations were measured on a Roche Cobas analyzer (Roche
Diagnostics). Urinary albumin excretion (UAE) rates were measured as described in two 24-hour
urine collections and the results were calculated as a mean for analysis.25 The estimated glomerular
Figure 1. Cohort Recruitment Flowchart
40 856 People assessed for eligibility
27 495 Excluded because they were
pregnant or had type 1 diabetes
2198 Excluded because they were
pregnant or had type 1 diabetes
1265 Excluded because of vitamin B12
missing values
58 Excluded because of vitamin B12
supplementation
30 890 People with UAC <10 mg/L 9966 People with UAC >10 mg/L
2592 Participated 6000 Participated
3395 Invited 7768 Invited
8592 Completed baseline screening
5571 Participants were eligible
6894 Participants completed
 second screening
5629 Participants with measured plasma
concentration of vitamin B12 
UAC indicates urinary albumin concentration.
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filtration rates (eGFRs) were calculated using the Chronic Kidney Disease Epidemiology Collaboration
combined creatinine–cystatin C equation.26
Clinical Measurements
Height and weight were measured with the participants standing without shoes or heavy outer
garments. Body mass index (BMI) was calculated by dividing weight in kilograms by height in meters
squared. Systolic and diastolic blood pressure values were recorded as the means of the last 2
recordings of the second visit.
Ascertainment of End Point
Participants were followed up from the date of the baseline visit until January 1, 2011. Data on
mortality were obtained from the municipal register, and the cause of death was obtained by linking
the number of the death certificate to the primary cause of death as coded by a physician from the
Central Bureau of Statistics.
Statistical Analysis
Data are presented as the mean (SD) or median (interquartile range [IQR]) for continuous variables
and percentages for categorical variables. Cross-sectional group differences among vitamin B12
plasma concentration groups at baseline were assessed by Welch 1-way test for normally distributed
data, Kruskal-Wallis test for skewed distributed data, and χ2 test for categorical variables.
Multivariable linear regression analyses were carried out to disclose the associations of vitamin B12
plasma concentrations with clinical covariates and laboratory parameters.
For the prospective analysis, we plotted cumulative Kaplan-Meier curves for mortality during
follow-up according to quartiles of vitamin B12 plasma concentrations. Quartile 1 was defined as
vitamin B12 plasma concentration less than 338.85 pg/mL (to convert to picomoles per liter, multiply
by 0.7378); quartile 2, 338.85 to 397.13 pg/mL; quartile 3, 397.14 to 455.41 pg/mL; and quartile 4,
more than 455.41 pg/mL. Time-to-event Cox proportional hazards models were used to assess the
hazard ratio (HR) and 95% CI of mortality among 5571 participants with full information at baseline.
We calculated HRs in models adjusted for covariates selected on the basis of physiological plausibility
and previous literature and organized in cumulative models of clinical significance. The cumulative
models depict the influence of different physiological components on the association of vitamin B12
plasma concentrations with mortality. The choice for certain confounder adjustments (eg, adjust for
systolic but not diastolic blood pressure) was made based on those variables that presented a
stronger association on the cross-sectional logistic regression analysis (eTable 1 in the Supplement).
The first model was adjusted for age and sex. The second model was further adjusted for relevant
clinical variables: race/ethnicity, type 2 diabetes, smoking behavior, alcohol consumption, and
education level, which were evaluated as dichotomous variables; BMI, systolic blood pressure, and
homocysteine level were evaluated as continuous variables. Model 3 included variables in model 2
plus relevant variables involved in hematological homeostasis, such as ferritin and hemoglobin levels
and mean corpuscular volume (continuous variables), which are also associated with plasma
concentrations of vitamin B12. Model 4 was adjusted for the same variables as model 3 plus TC to
high-density lipoprotein cholesterol ratio and glucose level (continuous variables), as a proxy for
cardiometabolic risk. Model 5 was adjusted for the variables in model 4 plus history of cancer
(dichotomous variable) and history of cardiovascular disease (CVD) (dichotomous variable), given
the previous reports of the association of high plasma concentrations of vitamin B12 with cancer
27
and the relevance of CVD in mortality risk. Model 6 was adjusted for the variables included in model
5 plus renal function (ie, eGFR and UAE rate as continuous variables), as this cohort was particularly
enriched with participants with a component of CKD. Finally, model 7 was adjusted for the variables
in model 6 plus aspartate aminotransferase, aspartate aminotransferase, alkaline phosphatase and
γ-glutamyltransferase levels (continuous variables), as previous literature also suggests an important
role of hepatic function on the metabolism of vitamin B12.
1 Hazard ratios were computed per 1-SD
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increment of plasma concentration of vitamin B12. Given the right-skewed distribution, vitamin B12
plasma concentration data were loge transformed. Hazard ratios were also computed according to
vitamin B12 plasma concentrations as a categorical variable, with the reference group as quartile 1. To
improve the graphic presentation of HRs, quartile 2 and quartile 3 were combined into a single
category. Proportionality of hazards assumptions were tested using weighted Schoenfeld residuals
for each variable and for every model as a whole. Additionally, interactions with age, eGFR, and UAE
rate were analyzed.
Furthermore, we conducted sensitivity analysis consisting of (1) individuals without history of
CVD; (2) individuals without history of cancer; (3) individuals without history of vitamin B12
deficiency, defined as plasma concentrations of vitamin B12 less than 200.60 pg/mL
28; (4)
individuals without history of vitamin B12 deficiency judged by plasma concentrations of
homocysteine greater than 2.03 mg/L (to convert to micromoles per liter, multiply by 7.397)28; (5) all
individuals with available information, including those with history of vitamin B12 supplementation;
and (6) individuals without mild to moderate loss of kidney function (eGFR <60 mL/min/1.73 m2). By
design, participants with an urinary albumin concentration of 10 mg/L or higher are overrepresented
in the PREVEND Study cohort. Therefore, a design-based analysis was performed to take this
overselection of participants with elevated UAE rates into account. This statistical weighting method
allows conclusions to be generalized to the general population. In addition, all-cause mortality
relative risks were estimated for each stratum of alcohol consumption, smoking behavior, and age.
Finally, prospective associations of plasma concentrations of vitamin B12 with risk of cancer mortality
and CVD mortality were assessed.
All statistical tests were 2-sided, and a P value less than .05 was considered statistically
significant. All statistical analyses were performed with R statistical software version 3.5.1 (R Project
for Statistical Computing). Data analysis was conducted from October 2, 2018, to February 22, 2019.
Results
Baseline Characteristics
Of 6894 PREVEND Study participants who completed the second round of screening, 5571
participants (mean [SD] age, 53.5 [12.0] years; 2830 [50.8%] men) were included in this study.
Participant characteristics at baseline are shown in Table 1. The median (IQR) vitamin B12 plasma
concentration was 394.42 (310.38-497.42) pg/mL (Table 1). A total of 195 participants (3.5%) had a
low vitamin B12 plasma concentration (<220.60 pg/mL). After dividing participants by plasma
concentration of vitamin B12, there were 1390 participants (mean [SD] age, 52.5 [12.3] years; 709
[51.0%] men) in quartile 1, the lowest concentration quartile; 2787 participants (mean [SD] age, 53.4
[11.9] years; 1444 [51.8%] men) in quartiles 2 and 3; and 1394 participants (mean [SD] age, 54.6 [11.6]
years; 677 [48.5%] men) in quartile 4, the highest concentration quartile. Participants within the
highest quartile of vitamin B12 plasma concentrations (>455.41 pg/mL) were more likely to be older
and have higher BMI and blood pressure. Additionally, those participants also had higher
concentrations of TC and glucose and higher UAE rates. Family history of CKD, history of cancer or
CVD, and educational levels were similar across the quartiles of vitamin B12 plasma concentrations
(Table 1).
Associations at Baseline
The associations of vitamin B12 plasma concentrations and other variables of interest were evaluated
with univariable and multivariable regression analysis (eTable 1 in the Supplement). In a fully adjusted
multivariable model, higher vitamin B12 plasma concentration remained positively associated with
use of lipid-lowering medication (β = 0.04 [95% CI, 0.01-0.07]; P = .04), high-density lipoprotein
cholesterol (β = 0.09 [95% CI, 0.05-0.13]; P < .001), ferritin (β = 0.05 [95% CI, 0.02-0.09];
P = .005), and hemoglobin (β = 0.15 [95% CI, 0.04-0.27]; P = .009) levels and inversely associated
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Table 1. Participant Characteristics According to Quartile of Plasma Concentration of Vitamin B12
Characteristic
Participants, No. (%)
P ValueaAll (N = 5571)
Vitamin B12 Plasma Concentration Quartile
1 (<338.85 pg/mL)
(n = 1390)




Men 2830 (50.8) 709 (51.0) 1444 (51.8) 677 (48.5) .12
Age, mean (SD), y 53.5 (12.0) 52.5 (12.3) 53.4 (11.9) 54.6 (11.6) <.001
White race/ethnicity 5292 (95.0) 1326 (95.4) 2651 (95.1) 1315 (94.3) .05
Education levelb .25
Low 2455 (44.0) 589 (42.3) 1234 (44.3) 632 (45.4)
Medium 1415 (25.5) 383 (27.7) 697 (25.0) 335 (24.0)
High 1701 (30.5) 418 (30.0) 856 (3.7) 427 (30.6)
BMI, mean (SD) 26.7 (4.3) 26.4 (4.1) 26.8 (4.4) 26.5 (4.4) <.001
Systolic BP, mean (SD), mm Hg 126.3 (18.6) 125.4 (18.4) 126.1 (18.4) 127.8 (19.2) .001
Diastolic BP, mean (SD), mm Hg 73.5 (9.1) 72.9 (9.1) 73.4 (9.1) 74.2 (9.1) <.001
Parental history of CKD 25 (0.5) 7 (0.5) 12 (0.4) 7 (0.5) .74
Parental history of type 2 diabetes 854 (15.3) 203 (14.6) 429 (15.4) 222 (15.9) .49
Type 2 diabetes 347 (6.2) 55 (3.95) 185 (6.63) 107 (7.67) <.001
Cancer history 262 (4.7) 71 (5.1) 131 (4.7) 60 (4.3) .60
CVD history 369 (6.6) 86 (6.2) 180 (6.4) 103 (7.3) .39
Smoking status
Never 1577 (28.3) 379 (27.3) 778 (27.9) 420 (30.1)
.01Former 2378 (42.7) 581 (41.8) 1180 (42.3) 617 (44.3)
Current 1547 (27.8) 409 (29.4) 796 (28.6) 342 (24.5)
Alcohol consumption, drinks/wk
<1 1424 (25.6) 352 (25.3) 707 (25.4) 365 (26.2)
.041-7 2653 (47.6) 670 (48.2) 1365 (49.0) 618 (44.3)
>7 1442 (25.9) 349 (25.1) 694 (24.9) 399 (28.6)
Using antihypertensive drugs 1404 (19.8) 227 (16.3) 563 (2.2) 314 (22.5) <.001
Using lipid-lowering drugs 460 (8.2) 93 (6.7) 237 (8.5) 130 (9.3) .05
Plasma concentration of vitamin B12,
median (IQR), pg/mL
394.42 (310.38-497.42) 261.59 (226.35-287.34) 394.42 (352.40-439.14) 626.19 (532.66-670.91) <.001
Ferritin, median (IQR), ng/mL 98.0 (48.0-134.6) 84.0 (44.0-152.2) 101.0 (49.0-174.0) 107.0 (52.0-196.2) <.001
Transferrin, mean (SD), mg/dL 259 (40) 261 (45) 257 (39) 258 (39) .03
Hemoglobin, mean (SD), g/dL 13.74 (1.22) 13.65 (1.21) 13.76 (1.22) 13.79 (1.22) .003
Hematocrit, mean (SD), % 40.88 (3.61) 40.65 (3.53) 4.92 (3.68) 41.03 (3.52) .01
MCV, mean (SD), μm3 90.4 (4.64) 90.8 (4.60) 9.3 (4.64) 90.1 (4.68) <.001
Homocysteine, mean (SD), mg/L 1.70 (0.59) 1.94 (0.71) 1.67 (0.54) 1.52 (0.48) <.001
TC, mean (SD), mg/dL 209.27 (40.54) 205.41 (38.61) 209.27 (40.93) 213.90 (40.93) <.001
HDL-C, mean (SD), mg/dL 48.26 (11.97) 47.10 (11.97) 48.26 (11.97) 49.42 (12.74) <.001
Triglycerides, median (IQR), mg/dL 99.12 (71.68-142.48) 97.35 (71.68-140.71) 100.00 (71.68-143.36) 98.23 (70.80-146.90) .69
TC/HDL-C ratio, median (IQR) 4.38 (3.55-5.38) 4.36 (3.60-5.39) 4.40 (3.55-5.37) 4.38 (3.51-5.37) .70
Glucose, mg/dL 46.49 (79.28-95.50) 84.68 (79.28-93.69) 86.49 (81.08-95.50) 86.49 (81.08-97.30) <.001
C-reactive protein, median (IQR), mg/L 1.34 (0.61-3.04) 1.18 (0.57-2.88) 1.36 (0.63-3.03) 1.47 (0.62-3.15) .01
eGFR, mean (SD), mL/min/1.73 m2 92.17 (17.10) 92.12 (16.8) 92.5 (17.1) 91.5 (17.2) <.001
UAE, median (IQR), mg/24 h 8.83 (6.09-16.25) 8.45 (6.00-14.69) 8.73 (6.08-15.90) 9.38 (6.26-18.09) <.001
ALT, median (IQR), U/L 17.0 (13.0-25.0) 16.0 (12.0-22.0) 18.0 (13.0-25.0) 19.0 (14.0-28.0) <.001
AST, median (IQR), U/L 22.0 (19.0-26.0) 22.0 (19.0-25.0) 22.0 (19.0-26.0) 23.0 (20.0-28.0) <.001
ALP, mean (SD), U/L 68.9 (20.3) 67.28 (18.9) 69.20 (2.5) 70.26 (20.9) <.001
GGT, median (IQR), U/L 24.0 (16.0-39.0) 22.0 (15.0-35.0) 24.0 (16.0-38.0) 27.0 (17.0-46.0) <.001
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; BMI, body mass index (calculated as weight in kilograms divided by
height in meters squared); BP, blood pressure; CKD, chronic kidney disease; CVD, cardio-
vascular disease; eGFR, estimated glomerular filtration rate; GGT, γ-glutamyltransferase;
HDL-C, high-density lipoprotein cholesterol; IQR, interquartile range; MCV, mean corpus-
cular volume; TC, total cholesterol; UAE, urinary albumin excretion.
SI conversion factors: To convert plasma concentration of vitamin B12 to picomoles per
liter, multiply by 0.7378; ferritin to picomoles per liter, multiply by 2.247; transferrin to
micromoles per liter, multiply by 0.123; hemoglobin to grams per liter, multiply by 10;
hematocrit to proportion of 1.0, multiply by 0.01; MCV to femtoliters, multiply by 1;
homocysteine to micromoles per liter, multiply by 7.397; cholesterol to millimoles per
liter, multiply by 0.0259; triglycerides to millimoles per liter, multiply by 0.0113; glucose
to millimoles per liter, multiply by 0.0555; C-reactive protein to nanomoles per liter,
multiply by 9.524; and ALT, AST, ALP, and GGT to microkatals per liter, multiply by 0.0167.
a P values represent the significance of difference across the quartiles of plasmatic
vitamin B12. P values were determined using a 1-way analysis of variance for normally
distributed data, Kruskal-Wallis test for skewed distributed data, and χ2 test for
categorical data.
b Education levels were defined as low, no, primary, basic vocational, and secondary
education; medium, senior secondary vocational and general senior secondary
education; or high, higher professional and higher academic education.
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with mean corpuscular volume (β = −0.09 [95% CI, −0.12 to −0.05]; P < .001), homocysteine level
(β = −0.34 [95% CI, −0.38 0.30]; P < .001), and eGFR (β = −0.11 [95% CI, −0.16, to −0.07]; P < .001).
Longitudinal Analysis
During median (IQR) follow-up of 8.2 (7.7-8.9) years, 226 participants (4.1%) died. Higher plasma
concentrations of vitamin B12, when analyzed as HR per 1 loge SD increase, were associated with
mortality after full adjustment (adjusted HR, 1.25 [95% CI, 1.06-1.47]; P = .006) (Table 2 and
Figure 2). Kaplan-Meier curves for mortality according to quartiles of vitamin B12 plasma
concentration are presented in Figure 3. There was an increased risk of all-cause mortality associated
with the top quartile of vitamin B12 concentrations (P for log-rank test <.001). In age- and
sex-adjusted Cox regression analysis that examined the vitamin B12 plasma concentration as a
categorical variable with quartile 1 as the reference group, the fourth quartile of vitamin B12 plasma
concentrations was associated with increased risk of mortality (HR, 1.73 [95% CI, 1.18-2.53]; P = .005)
(Table 2). The association remained significant after full adjustment (adjusted HR, 1.85 [95% CI, 1.16-
2.97]; P = .01) (Table 2). The proportional hazards assumptions were not violated for any of the
variables in the full model. The interaction terms of vitamin B12 plasma concentration with age, eGFR,
and UAE rate with all-cause mortality were not significant when included in either the crude or the
sex- and age-adjusted models.
Sensitivity Analyses
Excluding patients with a history of CVD, cancer, low plasma concentrations of vitamin B12, or high
plasma concentrations of homocysteine did not materially change the results (eTables 2, 3, 4, and 5 in
the Supplement). Inclusion of participants with history of vitamin B12 supplementation also did not
materially change the results (eTable 6 in the Supplement). In the analysis conducted after exclusion
of individuals with mild to moderate loss of kidney function (eGFR <60 mL/min/1.73 m2), there was
no association of plasma concentration of vitamin B12 with all-cause mortality after adjustment for
history of CVD (eTable 7 in the Supplement). Nonetheless, the results of the design-based analysis
are in line with the main results presented in Table 2 (eTable 8 in the Supplement). The relative risk of
all-cause mortality across the different strata of smoking behavior (eTable 9 in the Supplement),
Table 2. Associations of Plasma Concentration of Vitamin B12 With Risk of All-Cause Mortality
Model
Vitamin B12 Plasma Concentration
Per 1-SD Increment
Quartile 1 (<338.85 pg/mL)
Quartiles 2 and 3 (338.85-455.41 pg/mL) Quartile 4 (>455.41 pg/mL)
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Participants, No. 5571 1390 2787 1394
Deaths, No. 226 41 112 73
Unadjusted 1.22 (1.07-1.40) .002 1 [Reference] 1.35 (0.94-1.93) .10 1.76 (1.20-2.58) .003
Model 1a 1.22 (1.07-1.39) .003 1 [Reference] 1.34 (0.94-1.92) .10 1.73 (1.18-2.53) .005
Model 2b 1.25 (1.09-1.44) .001 1 [Reference] 1.34 (0.93-1.94) .12 1.84 (1.23-2.76) .002
Model 3c 1.26 (1.09-1.47) .002 1 [Reference] 1.38 (0.93-2.04) .10 1.77 (1.15-2.72) .009
Model 4d 1.26 (1.08-1.46) .003 1 [Reference] 1.38 (0.93-2.06) .10 1.72 (1.11-2.67) .01
Model 5e 1.24 (1.07-1.44) .005 1 [Reference] 1.38 (0.93-2.06) .10 1.70 (1.09-2.63) .01
Model 6f 1.25 (1.06-1.47) .006 1 [Reference] 1.41 (0.93-2.15) .10 1.84 (1.15-2.94) .01
Model 7g 1.25 (1.06-1.47) .006 1 [Reference] 1.38 (0.91-2.10) .12 1.85 (1.16-2.97) .01
Abbreviation: HR, hazard ratio.
SI conversion factor: To convert plasma concentration of vitamin B12 to picomoles per
liter, multiply by 0.7378.
a Adjusted for age and sex.
b Adjusted for model 1, ethnicity, body mass index, type 2 diabetes, smoking status (ie,
never, past, or current), alcohol consumption (ie, <1, 1-7, or >7 drinks/week), education
(ie, low, medium, or high), systolic blood pressure, and homocysteine level.
c Adjusted for model 2, ferritin level, hemoglobin, and mean corpuscular volume.
d Adjusted for model 3, total cholesterol to high-density lipoprotein cholesterol ratio, and
glucose level.
e Adjusted for model 4, history of cancer, and history of cardiovascular disease.
f Adjusted for model 5, estimated glomerular filtration rate, and urinary albumin
excretion rate.
g Adjusted for model 6, alanine aminotransferase, aspartate aminotransferase, alkaline
phosphatase, and γ-glutamyltransferase levels.
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alcohol consumption (eTable 10 in the Supplement), and age (eTable 11 in the Supplement) showed a
consistent association of higher plasma concentration of vitamin B12 with increased risk of all-cause
mortality. We found no independent associations of plasma concentration of vitamin B12 with cancer
mortality (eTable 12 in the Supplement) or with CVD mortality (eTable 13 in the Supplement).
Discussion
In this prospective population-based cohort study, we investigated the associations of plasma
concentration of vitamin B12 with all-cause mortality. Baseline characteristics, such as older age, high
blood pressure, reduced eGFR, and elevated UAE rate, as well as increased concentrations of liver
enzymes, were positively associated with higher plasma concentrations of vitamin B12, in agreement
with findings from other studies.3,8,11 While the cross-sectional associations as found in this study do
Figure 2. Association of Plasma Concentration of Vitamin B12
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not provide an insight for a particular cause of death, we observed that high circulating vitamin B12
plasma concentrations were associated with significantly higher risk of all-cause mortality. The
association remained significant after adjustment for established risk factors, including age, sex, BMI,
type 2 diabetes, tobacco use, and alcohol consumption, as well as biomarkers associated with renal
and liver function. We found no indication of change in this association by either renal function
or age.
In our study, the participants in the highest quartile of vitamin B12 had a mean age 1 year older
than the total cohort’s mean age (53.5 years). However, the association we found of plasma
concentration of vitamin B12 with all-cause mortality was independent of age. Previous studies have
explored such an association only in elderly people. A study by Salles et al6 reported an association
of high vitamin B12 plasma concentration with increased mortality risk among elderly individuals
(mean age, 86 years). On the other hand, a study by Robinson et al5 reported that vitamin B12 plasma
concentration levels were not associated with death risk in an elderly population. Moreover, in line
with previous reports, we did not find a statistically significant difference between sexes on the
association of vitamin B12 plasma concentration with all-cause mortality.
Contrary to the findings reported in a study by Arendt et al,27 we did not find a significant
association of vitamin B12 plasma concentration with risk of cancer mortality. Moreover, there was no
cross-sectional association between concentrations of vitamin B12 plasma concentration and cancer
history at baseline. In addition, the prospective association of vitamin B12 plasma concentration with
all-cause mortality was not changed by adjustment for history of cancer at baseline. Also in sensitivity
analyses, the association of plasma concentration of vitamin B12 with all-cause mortality persisted
after exclusion of participants with history of cancer.
Likewise, the association of all-cause mortality with high plasma concentrations of vitamin B12
could not be attributed to CVD. We demonstrated that adjustment for blood pressure, as well as lipid
profile and type 2 diabetes, did not change the association. Furthermore, in sensitivity analyses
conducted after exclusion of participants with history of CVD, the association remained. In addition,
plasma concentration of vitamin B12 was not associated with risk of CVD mortality. Such results are
in line with a 12-year follow-up study from 201929 that found that plasma concentrations of vitamin
B12 were not associated with the incidence risk of atherosclerotic disease.
Considering the universal role of the 1-carbon pathway in mammals, the explanation of the
described association seems to rely in the role of vitamin B12 in the homeostasis of nonproliferative
tissues6 rather than proliferative tissues,1 such as the bone marrow and other hematopoietic tissues,
as we demonstrated that this association was independent of cancer history.
To date, the underlying mechanism of the association of plasma concentration of vitamin B12
with mortality is incompletely understood, to our knowledge. The proposed mechanisms to explain
the association are that high vitamin B12 plasma concentrations may represent a response to
increased release of vitamin B12 from liver storage, decreased clearance, upregulation of haptocorrin
and transcobalamin synthesis, or diminished affinity of vitamin B12 for transporter proteins.
1,3 Those
situations are often present as a consequence of liver damage or CKD, which could be represented by
the baseline association of high plasma concentrations of vitamin B12 with elevated concentrations
of hepatic enzymes. Nonetheless, a definite mechanism has not been described, to our
knowledge.14,30
The results of this study could also be clinically interpreted in the context of oral vitamin
supplementation. Concern about the excess intake of vitamins, particularly vitamin B12, has gained
attention. A 2010 study by Løland et al31 reported that vitamin B supplementation had no beneficial
effect on the progression of coronary artery disease, as had been hypothesized previously. Moreover,
in a prospective study with 75 864 women,32 vitamin B12 supplementation was associated with an
increased risk of hip fracture. In that sense, our results may also suggest that caution should be taken
when considering vitamin B12 supplementation in the absence of vitamin B12 deficiency.
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Strengths and Limitations
This study has several strengths. To our knowledge, this is the first study reporting on the association
of all-cause mortality with higher vitamin B12 plasma concentrations in the general population in
which the vitamin B12 plasma concentration measurement was performed in unselected individuals,
as we excluded participants with B12 supplementation, which is one source of bias in other studies.
27
Moreover, we adjusted our results for several confounding variables, including liver function
parameters, and found that the association remained, whereas other authors have reported loss of
significance after such adjustment.11 Another strength of this study is the implementation of a robust
method of plasma concentration of vitamin B12 quantification. The accuracy of the assay that we
used has been evaluated using the vitamin B12 World Health Organization International Standard.
33
Moreover, it has been reported that the Elecsys Vitamin B12 assay is not affected by anti–intrinsic
factor antibodies, enhancing the reliability of this assay.34 Furthermore, this is the largest study to
date reporting on such an association, to our knowledge, which enabled us to carry out sufficiently
powered multivariable adjusted analyses and testing the robustness of the findings using several
sensitivity analyses to provide solid evidence. Finally, the PREVEND cohort was enriched for
increased albumin excretion. We therefore conducted design-based analyses, making our results
valid for the general population.
Several limitations of this study also need to be addressed. First, the PREVEND cohort study
mainly comprises individuals of European ancestry, which could limit extrapolation of our findings to
other races/ethnicities. Second, we did not have measurements of vitamin B12 plasma concentrations
beyond baseline assessment, which limited us to evaluate the regression dilution of vitamin B12.
Third, we only had access to pharmacy records on injectable vitamin B12 supplementation, but not for
over-the-counter tablets, which could limit the implication of cobalamin supplementation; likewise,
we had no data on reason for performing the vitamin B12 injections. Furthermore, it is worth noting
that residual confounding is an important limitation in all observational studies. To further evaluate
the associations of well-known mortality risk factors, we provided a supplementary analysis of
all-cause mortality relative risks for each stratum of alcohol consumption as well as smoking behavior.
Additionally, dietary patterns can also be influence plasma concentration of vitamin B12 and risk of
mortality. In the PREVEND cohort, detailed dietary information was not available, which we consider
a limitation. Therefore, the possibility of a noncausal association should not be discarded and
deserves further investigation.
Conclusions
In this population-based cohort study, high plasma concentrations of vitamin B12 were associated
with an increased risk of all-cause mortality. The prospective association was independent of age,
renal function, and other comorbidities, such as history of cancer. Further investigation is needed to
unravel the complexity of 1-carbon metabolism in different mortality causes, such as cardiometabolic
disease and cancer.
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